Access-Site Complications in Transfemoral Neuroendovascular Procedures: A Systematic Review of Incidence Rates and Management Strategies

Mazen Oneissi  
*Baylor College of Medicine*

Ahmad Sweid, MD  
*Thomas Jefferson University*

Stavropoula Tjoumakaris  
*Thomas Jefferson University*

David Hasan  
*University of Iowa*

Recommended Citation  
Oneissi, Mazen; Sweid, MD, Ahmad; Tjoumakaris, Stavropoula; Hasan, David; Gooch, MD, Michael R.; Rosenwasswer MD, Robert H.; and Jabbour, Pascal, "Access-Site Complications in Transfemoral Neuroendovascular Procedures: A Systematic Review of Incidence Rates and Management Strategies" (2020). *Department of Neurosurgery Faculty Papers*. Paper 125.  
https://jdc.jefferson.edu/neurosurgeryfp/125

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Neurosurgery Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Access-Site Complications in Transfemoral Neuroendovascular Procedures: A Systematic Review of Incidence Rates and Management Strategies

BACKGROUND: The femoral artery is the most common access route for cerebral angiography and neurointerventional procedures. Complications of the transfemoral approach include groin hemorrhages and hematomas, retroperitoneal hematomas, pseudoaneurysms, arteriovenous fistulas, peripheral artery occlusions, femoral nerve injuries, and access-site infections. Incidence rates vary among different randomized and nonrandomized trials, and the literature lacks a comprehensive review of this subject.

OBJECTIVE: To gather data from 16 randomized clinical trials (RCT) and 17 nonrandomized cohort studies regarding femoral access-site complications for a review paper. We also briefly discuss management strategies for these complications based on the most recent literature.

METHODS: A PubMed indexed search for all neuroendovascular clinical trials, retrospective studies, and prospective studies that reported femoral artery access-site complications in neurointerventional procedures.

RESULTS: The overall access-site complication rate in RCTs is 5.13%, while in non-RCTs, the rate is 2.78%. The most common complication in both groups is groin hematoma followed by access-site hemorrhage and femoral pseudoaneurysm. On the other hand, wound infection was the least common complication.

CONCLUSION: The transfemoral approach in neuroendovascular procedures holds risk for several complications. This review will allow further studies to compare access-site complications between the transfemoral approach and other alternative access sites, mainly the transradial approach, which is gaining a lot of interest nowadays.

KEY WORDS: Neuroendovascular, Femoral artery, Groin Hematoma, Femoral artery pseudoaneurysm


DOI: 10.1093/ons/opa096

Since the old use of interventional methods in the diagnosis and treatment of certain cerebral vascular disorders and stroke, the femoral artery has been the preferred access point for the introduction of catheters in the diagnosis and treatment of certain cerebral vascular disorders and stroke.1-3 However, the transfemoral approach has been associated with a wide array of access-site complications, ranging in severity from minor complications requiring minimal treatment to life-threatening complications requiring aggressive, life-saving surgical interventions. The most common access-site complication is groin hematoma, which may vary in size, while one of the most serious complications is retroperitoneal hematoma, which may lead to hemorrhagic shock and death if not quickly diagnosed and treated.2-5 Among other complications are access-site hemorrhages, femoral artery dissections and pseudoaneurysms, arteriovenous (AV) fistulas, peripheral artery occlusions, femoral nerve injuries, and access-site infections.2 Many studies have reported various incidence rates of these complications. While the literature regarding access-site complications in coronary interventional procedures is well published,
publications pertaining to a comprehensive review of access-site complications are lacking for neuroendovascular procedures. In this article, we review the literature, including randomized clinical trials, retrospective and prospective cohorts, and certain case reports to provide a systematic review that summarizes incidence rates as well as management strategies for access-site complications related to the transfemoral approach in neurointerventional procedures.

METHODS

Using PubMed database, we performed a literature search without time limitations for all articles using different combinations of the terms transfemoral, neurointervention, neuroendovascular, interventional neurology, and femoral artery. Articles were then classified as randomized clinical trials (RCTs) and non-RCTs. Abstracts were screened to determine if the study matches our requirements, mainly being related to neurointerventional procedures. Then, full texts were read in depth to determine whether access-site complications were discussed and if incidence data were available. Articles were searched for adverse events, complications, and outcomes in the text, tables, or supplementary material. Articles that did not provide data about the incidence rates of access-site complications were excluded. For RCTs, the website clinicaltrials.gov was also searched for publicly available results that included data about adverse events and access-site complications. RCTs with no data in published articles or through clinicaltrials.gov were excluded. Additionally, case reports of rare complications were discussed in a subsection in the discussion.

Incidence rates were calculated by dividing the number of occurrences of each access-site complication by the total number of patients who underwent a neurointerventional procedure using the transfemoral approach. If one patient underwent multiple independent procedures, that patient was counted twice in the total population. The total incidence rate of access-site complications for each study is calculated by adding all incidents of access-site complications divided by the total number of patients. The average incidence rate of a certain complication among multiple studies is calculated by adding the individual number of incidents of that complication in all studies divided by the total number of patients only from studies that reported that complication. Studies that frankly report no incidents of that particular complication are included in the total population, while those that do not report the complication are not included. By excluding these studies from the total population, we overcome the bias from selective reporting among studies. Due to the nature of the manuscript, institutional review board approval and patient consent were not sought.

RESULTS

Study Selection

Our search on PubMed found 30 RCTs and 54 non-RCTs of various interventional procedures, while the search on clinicaltrials.gov gave us 29 RCTs all related to neurointerventional procedures. A total of 19 RCTs were eliminated as duplicates between the 2 searches. Out of the remaining 40 RCTs, only 16 published data about access-site complications in the transfemoral approach and were included in our review. Out of the 54 non-RCTs, 25 were eliminated at the level of title and abstract screening either because they are related to cardiovascular procedures or because the management was medical, not requiring an endovascular procedure, whether diagnostic or interventional. Out of the remaining 29 non-RCTs, 12 were excluded after full-text reading due to the lack of data regarding access-site complications. The remaining 17 non-RCTs were included in our review. In total, we reviewed 16 RCTs and 17 non-RCTs reporting access-site complication rates (Figure 1). Additionally, 5 non-RCTs tackling the use of different vascular closure devices (VCDs) have been separately included in our study.

Study Characteristics

Among the 16 RCTs, 10 were related to stroke management. These were IMS-II, IMS-III, ESCAPE, EXTEND-IA, REVASCAT, RIVER JAPAN, SWIFT, THRACE, STAR, and SWIFT-PRIME. Two RCTs (PUFS and PFLEX) and 1 registry (The Buenos Aires Experience) were related to the use of pipeline device for the treatment of cerebral aneurysms. One RCT (ENACT) was related to the use of coiling in treating cerebral aneurysm, and 2 RCTs (CREST and RADCAR) were related to carotid artery stenting. Excluded RCTs were MR CLEAN, MR RESCUE, THERAPY, SYNTHESIS, PISTE, ASTER, DAWN, TREVO, ADAPT, IntrePED, PREMIER, PITA, ASPIRe, MATRIX, TEAM, ISAT, SAMMPRIS, ATENA, CLARITY, WEB-IT, WEBCAST 1, WEBCAST 2, SAPPHIRE, and ARUBA.

From the 17 non-RCTs included in our study, 7 were related to diagnostic cerebral angiography, 2 were related to cerebral aneurysm coiling, 2 were related to the use of flow diverters to treat cerebral aneurysms, 1 was related to carotid artery stenting, 1 was related to intraarterial chemotherapy delivery, 1 was related to mechanical thrombectomy, and 3 were a mixture of several neurointerventional procedures.

DISCUSSION

Access-Site Hemorrhage

Access-site hemorrhage is a relatively common complication of interventional procedures using the transfemoral approach and is considered a leading cause of groin hematomas as well as retroperitoneal hematomas. Risk factors include use of anticoagulation, insufficient manual compression, and early ambulation. For the sake of this review, we are defining access-site hemorrhage as bleeding from the puncture site without including contained subcutaneous and retroperitoneal hematomas, as these are described in separate sections. Seven RCTs report incidents of groin hemorrhage at rates ranging from 0.78% to 2.61% with an average of 2.06%, while one non-RCT reports an incidence rate of 0.59% (Table 1).
**Groin Hematoma**

Groin hematoma is the most common complication when using the femoral artery as an access point in both cardiac and neurointerventional procedures.\(^3,5,14\) Groin hematomas occur shortly after sheath removal due to failure to control bleeding from the femoral artery. Risk factors include obesity, use of anticoagulants, large sheaths, early ambulation, and peripheral vascular disease.\(^15\) It is believed that puncturing below the femoral bifurcation as well as poor hemostatic techniques increase the risk of developing a groin hematoma (Figure 2A).\(^2,15\)

A total of 12 RCTs reported incidence rates of groin hematomas between 0.23% and 10.68% with an average of 2.49%, \(^6-10,12,13,16-20\) while non-RCTs reported an incidence rate of 0.03% to 8.1% with an average of 2.89%.\(^5,14,21-27\) Differences in occurrence rates are partly due to the differences in defining what constitutes a hematoma. Additionally, some studies only reported hematomas that are larger than a certain size threshold. The ESCAPE and REVASCAT trials reported incidence rates of groin hematoma as high as 9.09% and 10.68%, respectively, while rates were as low as 0.63% and 0.99% in the CREST and STAR trials, respectively (Tables 1 and 2).\(^7,13,17,20\)

The literature regarding the use of VCDs to reduce the risk of groin hematomas compared to manual compression is variable. A prospective multicenter registration study by Sato et al\(^30\) showed a significant decrease in incidence rates of groin hematomas when AngioSeal STS Plus VCD (Terumo) is used vs manual compression (5.04% vs 34.55%, \(P\)-value < .001). Moreover, hemostasis time was significantly shorter in the VCD group than
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>(total)</th>
<th>N</th>
<th>Groin hematoma</th>
<th>Groin hemorrhage</th>
<th>Retroperitoneal hematoma</th>
<th>Femoral (pseudo) aneurysm</th>
<th>Artery occlusion</th>
<th>Femoral nerve injury</th>
<th>Wound infection</th>
<th>All complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>STROKE IMS-II8</td>
<td>2007</td>
<td>81</td>
<td></td>
<td>1</td>
<td>1.23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2013</td>
<td>434</td>
<td></td>
<td>16</td>
<td>3.69</td>
<td>6</td>
<td>1.38</td>
<td>2</td>
<td>0.46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ESCAPE7</td>
<td>2015</td>
<td>165</td>
<td></td>
<td>15</td>
<td>9.09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EXTEND-IA17</td>
<td>2015</td>
<td>35</td>
<td></td>
<td>1</td>
<td>2.86</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REVASCAT7</td>
<td>2015</td>
<td>103</td>
<td></td>
<td>11</td>
<td>10.68</td>
<td>2</td>
<td>1.94</td>
<td>1</td>
<td>0.97</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RIVER JAPAN8</td>
<td>2016</td>
<td>49</td>
<td></td>
<td>1</td>
<td>2.04</td>
<td>1</td>
<td>2.04</td>
<td>2</td>
<td>4.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SWIFT</td>
<td>2016</td>
<td>113</td>
<td></td>
<td>2</td>
<td>1.77</td>
<td>1</td>
<td>0.88</td>
<td>2</td>
<td>1.77</td>
<td></td>
<td></td>
</tr>
<tr>
<td>THRACE6</td>
<td>2016</td>
<td>204</td>
<td></td>
<td>3</td>
<td>1.47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STAR10</td>
<td>2017</td>
<td>202</td>
<td></td>
<td>2</td>
<td>0.99</td>
<td></td>
<td></td>
<td>1</td>
<td>0.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SWIFT PRIME10</td>
<td>2017</td>
<td>98</td>
<td></td>
<td>1</td>
<td>1.02</td>
<td>1</td>
<td>1.02</td>
<td>1</td>
<td>1.02</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pipeline Buenos Aires18</td>
<td>2009</td>
<td>53</td>
<td></td>
<td>5</td>
<td>9.43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PUFS14</td>
<td>2018</td>
<td>107</td>
<td></td>
<td>1</td>
<td>0.93</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLEX</td>
<td>2019</td>
<td>50</td>
<td></td>
<td>1</td>
<td>2.3</td>
<td>2</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coil ENACT17</td>
<td>2012</td>
<td>92</td>
<td></td>
<td>1</td>
<td>1.09</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carotid CREST13</td>
<td>2011</td>
<td>1262</td>
<td></td>
<td>8</td>
<td>0.63</td>
<td>33</td>
<td>2.61</td>
<td>4</td>
<td>0.32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RADCAR2</td>
<td>2014</td>
<td>128</td>
<td></td>
<td>6</td>
<td>4.69</td>
<td>1</td>
<td>0.78</td>
<td>1</td>
<td>0.78</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total n</td>
<td></td>
<td>71</td>
<td></td>
<td>45</td>
<td>64.72</td>
<td>13</td>
<td>18.4</td>
<td>6</td>
<td>8.34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total N</td>
<td></td>
<td>2847</td>
<td></td>
<td>2188</td>
<td>76.62</td>
<td>2284</td>
<td>80.76</td>
<td>982</td>
<td>34.47</td>
<td>547</td>
<td>19.16</td>
</tr>
<tr>
<td>Average incidence rate</td>
<td></td>
<td>2.49%</td>
<td></td>
<td>2.06%</td>
<td>0.57%</td>
<td>0.61%</td>
<td>0.5%</td>
<td>0.41%</td>
<td>0.37%</td>
<td>5.33%</td>
<td></td>
</tr>
</tbody>
</table>
in the manual compression group (4.4 vs 15.0 min, \( P < .001 \)). On the other hand, incidence rates in 5 non-RCTs reporting groin hematoma as a complication of the transfemoral approach while using VCDs ranged between 0.49% and 5.04% with an average rate of 1.38% (Table 3).30-34

**Retroperitoneal Hematoma**

Retroperitoneal hematoma, a relatively rare complication of femoral puncture, develops either due to an uncontrolled groin hematoma that expands in size or a femoral puncture above the level of the inguinal ligament (Figure 2B).4,15 It is considered...
### TABLE 2. Transfemoral Complications in Observational Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>N</th>
<th>Groin hematoma</th>
<th>Groin hemorrhage</th>
<th>Retroperitoneal hematoma</th>
<th>Femoral (pseudo) aneurysm</th>
<th>Arteriovenous fistula</th>
<th>Artery occlusion</th>
<th>Femoral nerve Injury</th>
<th>Wound infection</th>
<th>All complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huckman et al</td>
<td>1979</td>
<td>361</td>
<td>6</td>
<td>1.66</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heiserman et al</td>
<td>1994</td>
<td>1000</td>
<td>81</td>
<td>8.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Willinsky et al</td>
<td>2008</td>
<td>2899</td>
<td>14</td>
<td>0.48</td>
<td>1</td>
<td>0.03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaufmann et al</td>
<td>2007</td>
<td>19390</td>
<td>828</td>
<td>4.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dawkins et al</td>
<td>2007</td>
<td>2924</td>
<td>12</td>
<td>0.41</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fifi et al</td>
<td>2009</td>
<td>3636</td>
<td>1</td>
<td>0.03</td>
<td>1</td>
<td>0.03</td>
<td>2</td>
<td>0.06</td>
<td>1</td>
<td>0.03</td>
<td>12</td>
</tr>
<tr>
<td>Shen et al</td>
<td>2018</td>
<td>644</td>
<td>10</td>
<td>1.55</td>
<td>1</td>
<td>0.16</td>
<td>1</td>
<td>0.16</td>
<td>0</td>
<td>0</td>
<td>12</td>
</tr>
<tr>
<td>Mendiz et al</td>
<td>2016</td>
<td>674</td>
<td>4</td>
<td>0.59</td>
<td>2</td>
<td>0.3</td>
<td>1</td>
<td>0.15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Im et al</td>
<td>2009</td>
<td>370</td>
<td>1</td>
<td>0.27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cavalanti et al</td>
<td>2013</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelm et al</td>
<td>1999</td>
<td>392</td>
<td>10</td>
<td>2.55</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Horowitz et al</td>
<td>1998</td>
<td>1929</td>
<td>10</td>
<td>0.52</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kelkar et al</td>
<td>2013</td>
<td>2918</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Qureshi et al</td>
<td>2018</td>
<td>270</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shah et al</td>
<td>2015</td>
<td>472</td>
<td>2</td>
<td>0.42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lubcz et al</td>
<td>2011</td>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burrows et al</td>
<td>2014</td>
<td>93</td>
<td>1</td>
<td>1.08</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total n</td>
<td>975</td>
<td></td>
<td>4</td>
<td>5</td>
<td>20</td>
<td>2</td>
<td>30</td>
<td>4</td>
<td>10</td>
<td></td>
<td>1056</td>
</tr>
<tr>
<td>Total N</td>
<td>33740</td>
<td></td>
<td>674</td>
<td>4352</td>
<td>10347</td>
<td>2943</td>
<td>25347</td>
<td>270</td>
<td>27966</td>
<td>38014</td>
<td></td>
</tr>
<tr>
<td>Average incidence rate</td>
<td>2.89%</td>
<td>0.59%</td>
<td>0.11%</td>
<td>0.19%</td>
<td>0.07%</td>
<td>0.12%</td>
<td>1.48%</td>
<td>0.4%</td>
<td>2.78%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE 3. Transfemoral Complications in Observational Studies Using Different Vascular Closure Devices (VCDs)

<table>
<thead>
<tr>
<th>Study</th>
<th>VCD</th>
<th>Year</th>
<th>Total N</th>
<th>Groin hematoma</th>
<th>Groin hemorrhage</th>
<th>Retroperitoneal hematoma</th>
<th>Femoral (pseudo) aneurysm</th>
<th>Arteriovenous fistula</th>
<th>Artery occlusion</th>
<th>Femoral nerve injury</th>
<th>Wound infection</th>
<th>Total complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sato et al. 30</td>
<td>Angio-seal/STS Plus</td>
<td>2017</td>
<td>119</td>
<td></td>
<td>6</td>
<td>5.04</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.84</td>
</tr>
<tr>
<td>Geyik et al. 31</td>
<td>Angio-seal/STS 2007</td>
<td>1443</td>
<td>3</td>
<td>7</td>
<td>0.49</td>
<td>0.97</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.14</td>
</tr>
<tr>
<td>Goto et al. 32</td>
<td>EXOSEAL</td>
<td>2017</td>
<td>332</td>
<td>8</td>
<td>2.41</td>
<td>0.28</td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>Grandhi et al. 33</td>
<td>Mynx 2014</td>
<td>93</td>
<td>71</td>
<td>7.18</td>
<td>1.8</td>
<td>0.3</td>
<td>0.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.32</td>
</tr>
<tr>
<td>Grandhi et al. 34</td>
<td>EXOSEAL 2015</td>
<td>441</td>
<td>7092</td>
<td>6.96</td>
<td>5.12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.14</td>
</tr>
</tbody>
</table>

From the reviewed 40 RCTs, 8 reported the incidence of retroperitoneal hemorrhage ranging from 0.32% to 1.77% with an average of 0.57% (Table 1).6,8-10,12,13,36,37 Four non-RCTs reported incidence rates between 0.03% and 5% with an average of 0.11% (Table 2).11,23,38,39 However, it is worth noting that 2 of these studies with incidence rates of 4.33% and 5% have a relatively low total number of enrolled subjects of 22 and 20, respectively, and only one incidence of retroperitoneal hematoma in each, which accounted for the relatively high incidence rate.

Although relatively rare, retroperitoneal hematoma is a serious complication that may lead to death if not treated properly. The management of retroperitoneal hematoma is mainly conservative for hemodynamically stable with intensive care unit observation, fluid resuscitation, blood transfusion, and reversal of anticoagulation. In unresponsive cases, further intervention is warranted, with preference for percutaneous interventional procedures over surgery.35,40,41 Options include embolization by coiling, gelatin, and/or polyvinyl alcohol. Other options include balloon tamponade of the common femoral artery and balloon catheter delivery of intra-arterial thrombin. Surgical intervention is entertained if less invasive procedures fail.42

Femoral Artery Pseudoaneurysm and Dissection

Femoral artery pseudoaneurysm is a known but uncommon complication of interventional procedures, especially via the transfemoral approach. A pseudoaneurysm is a hematoma with persistent communication with the artery, and it is usually limited to the area surrounding the common femoral artery (Figure 2C).43 Although not always present, a differentiating aspect of femoral pseudoaneurysms from other groin hematomas is the presence of pulsation due to the persistent communication between the pseudoaneurysm and the artery.44 A femoral puncture below the bifurcation is a risk factor.5,5,4,3 Other risk factors include advanced age, obesity, gender (female > male), use of anticoagulants, and lower platelet count.3

Six RCTs report incidence rates of femoral pseudoaneurysms between 0.23% and 2.04% with an average of 0.61% (Table 1).6,7,9,20,45,46 The incidence rate in 7 non-RCTs ranged between 0.03% and 3.23% with an average of 0.19% (Table 2).5,11,21,23,25,28,29

On the other hand, femoral artery dissection is an injury to the vessel wall leading to the disruption of its layers without complete rupture (Figure 2D). Arterial dissection leads to blood flow disturbance and may result in arterial occlusion. Three non-RCTs report incidence rates of femoral or iliac artery dissection between 0.1% and 0.27%, with an average rate of 0.14% (Table 2).14,22,47

one of the most serious and difficult-to-diagnose complications. Symptoms are nonspecific and may include suprapubic and fullness (most common), severe back and lower quadrant abdominal pain, and lower extremity pain. Patients may also develop hypotension that may require blood transfusions or urgent surgical intervention.4,35

From the reviewed 40 RCTs, 8 reported the incidence of retroperitoneal hemorrhage ranging from 0.32% to 1.77% with an average of 0.57% (Table 1).6,8-10,12,13,36,37 Four non-RCTs reported incidence rates between 0.03% and 5% with an average of 0.11% (Table 2).11,23,38,39 However, it is worth noting that 2 of these studies with incidence rates of 4.33% and 5% have a relatively low total number of enrolled subjects of 22 and 20, respectively, and only one incidence of retroperitoneal hematoma in each, which accounted for the relatively high incidence rate.

Although relatively rare, retroperitoneal hematoma is a serious complication that may lead to death if not treated properly. The management of retroperitoneal hematoma is mainly conservative for hemodynamically stable with intensive care unit observation, fluid resuscitation, blood transfusion, and reversal of anticoagulation. In unresponsive cases, further intervention is warranted, with preference for percutaneous interventional procedures over surgery.35,40,41 Options include embolization by coiling, gelatin, and/or polyvinyl alcohol. Other options include balloon tamponade of the common femoral artery and balloon catheter delivery of intra-arterial thrombin. Surgical intervention is entertained if less invasive procedures fail.42

Femoral Artery Pseudoaneurysm and Dissection

Femoral artery pseudoaneurysm is a known but uncommon complication of interventional procedures, especially via the transfemoral approach. A pseudoaneurysm is a hematoma with persistent communication with the artery, and it is usually limited to the area surrounding the common femoral artery (Figure 2C).43 Although not always present, a differentiating aspect of femoral pseudoaneurysms from other groin hematomas is the presence of pulsation due to the persistent communication between the pseudoaneurysm and the artery.44 A femoral puncture below the bifurcation is a risk factor.5,5,4,3 Other risk factors include advanced age, obesity, gender (female > male), use of anticoagulants, and lower platelet count.3

Six RCTs report incidence rates of femoral pseudoaneurysms between 0.23% and 2.04% with an average of 0.61% (Table 1).6,7,9,20,45,46 The incidence rate in 7 non-RCTs ranged between 0.03% and 3.23% with an average of 0.19% (Table 2).5,11,21,23,25,28,29

On the other hand, femoral artery dissection is an injury to the vessel wall leading to the disruption of its layers without complete rupture (Figure 2D). Arterial dissection leads to blood flow disturbance and may result in arterial occlusion. Three non-RCTs report incidence rates of femoral or iliac artery dissection between 0.1% and 0.27%, with an average rate of 0.14% (Table 2).14,22,47
The management of femoral pseudoaneurysms is usually conservative. Observation plays an important role until a certain size threshold. The widely used threshold is 3 cm. Another approach is ultrasound-guided compression (UGC) of the pseudoaneurysm neck to block its blood flow for an average of 30 min while maintaining femoral artery blood flow. Stasis of blood in the pseudoaneurysm leads to its thrombosis. Another approach with higher success rate is duplex-guided thrombin injection, in which thrombin is injected in the aneurysm sac. Surgical intervention is preserved for large pseudoaneurysms with superimposed skin necrosis, infection, or nerve compression.3

Peripheral Arterial Occlusion

Many factors contribute to arterial occlusion in the peripheral circulation after transfemoral catheterization, including arterial stenosis, thrombosis, and dissection (Figure 2D and 2E). Symptoms include lower limb pain, claudication, cold limb, or pale color of lower extremity. Symptoms may appear within 24 h postcatheterization but can also be delayed or appear only after long-distance ambulation. In severe cases, lower extremity ischemia may occur requiring aggressive interventional or surgical treatment.

Peripheral artery occlusion is a relatively rare complication of the transfemoral approach in neurointerventional procedures. Three RCTs report incidence rates between 0.23% and 2.04%, with an average rate of 0.5% (Table 1).6,9,45 Four non-RCTs report incidence rates between 0.05% and 0.93% with an average of 0.12% (Table 2).23-25.27 Reported cases included 1 popliteal artery and 1 iliac artery thrombosis, while the other cases were unspecified. Higher incidence rates of arterial occlusion ranging between 0.14% and 6.86% were reported when VCDs were used for hemostasis (Table 3).1,31 Corley et al48 reported a case of right common femoral artery occlusion in a 26-yr-old female undergoing a transfemoral interventional procedure for AVM embolization. A 6F AngioSeal closure device was used to close the arteriotomy. The patient had the typical symptoms, and right common femoral artery occlusion was confirmed by radiology. Intraoperatively, it was found that the AngioSeal device was occluding the artery.

AV Fistula

An AV fistula is an abnormal communication between an artery and a vein (Figure 2F).43 AV fistula formation is a rare complication of femoral artery catheterization. A puncture below the femoral bifurcation at the superficial femoral artery is a risk factor.2,49 Other risk factors include arterial hypertension, female gender, left groin puncture, and mode and intensity of anticoagulation. AV fistulas lead to left-to-right hemodynamic shunting, which may reduce blood flow in the downstream vascular bed and may lead to cardiac failure if left untreated.30

None of the 40 reviewed RCTs reported any case of AV fistula, while 3 non-RCTs reported incidence rates between 0% and 0.27% with an average rate of 0.07% (Table 2).3,25,47

Femoral Nerve Injury

The femoral nerve enters the thigh through the femoral triangle lateral to the femoral artery separated from it by continuous iliopectineal fascia (Figure 3). Due to the multiple manipulations in the vicinity of the femoral artery, the femoral nerve is at risk of compression injury. It manifests as pure sensory symptoms including pain, paresthesia, and sensory loss. Additionally, the injury may affect the anterior, medial, and lateral cutaneous branches of the femoral nerve.52

Two RCTs, SWIFT and RADCAR, reported incidence rates between 0% and 0.88% with an average rate of 0.41%
A study by Dudeck et al.\(^5\) showed a significant decrease in time to arterial puncture and number of attempts for successful puncturing only in patients with weak femoral pulse or leg circumference \(>60 \text{ cm}\). Another recently published randomized controlled trial (SURF) showed that there was no difference in the complication rates between standard and ultrasound guidance \((P = .76)\). However, ultrasound guidance reduced mean access time \((93 \text{ vs } 111 \text{ s}; P = .009)\), attempts \((1.47 \text{ vs } 1.9; P < .0001)\), and venipuncture \((4.1\% \text{ vs } 9.2\%; P < 0.0001)\) and improved first-pass success \((73\% \text{ vs } 59.7\%; P = .0001)\). On the other hand, a single-center retrospective cohort study on 387 patients undergoing transcatheter aortic valve replacement (TAVR) found that the routine use of ultrasound in transfemoral TAVR was associated with significant reductions in access-related vascular and bleeding complications \((\text{odds ratio [OR]} = 0.42 \text{ [95\% CI, 0.25-0.70]; } P < .01)\).\(^5\) Another recent meta-analysis of 5 RCTs found that ultrasound guidance significantly improves time to access \((\text{weighted mean difference: } 24.90 \text{ min, 95\% CI 12.41-37.38})\), first-pass success rate \((\text{OR } 2.97; 95\% \text{ CI } 1.49-5.92))\), and total complication rate \((\text{OR } 0.42, 95\% \text{ CI } 0.23-0.77)\) but did not have any significant influence on the incidence rate of individual complications like groin hematoma, retroperitoneal hematoma, or pseudoaneurysm.\(^5\)

### Access-Site Infection

Surgical site infection is a common complication of all invasive procedures, especially with the introduction of permanent foreign bodies. In neurointerventional procedures, groin infection is a rare but serious complication, especially with the use of femoral artery closure devices. In 2 RCTs, IMS-III and SWIFT, the incidence rates were 0.23% and 0.88%, respectively, with an average of 0.37%. The use of VCDs was not specified in these trials.\(^5\) On the other hand, non-RCTs reported incidence rates ranging between 0% and 0.84% with an average rate of 0.23% (Table 3).\(^3\)

To prevent procedure-associated infections, the Centers for Disease Control (CDC) recommends the use of sterile techniques in catheterization procedures. Prophylactic use of antibiotics is not recommended unless the patient is immunocompromised or a definite wound contamination is suspected during the procedure.\(^5\)

### Minor vs Major Complications

Access-site-related complications can be categorized as minor vs major complication. The former includes groin hematoma and groin hemorrhage, while the latter includes retroperitoneal hematomas, AV fistulae, femoral artery pseudoaneurysms, femoral artery dissection, femoral nerve injury, arterial occlusion, and wound infection. Table 4 shows the distribution of complications between these 2 groups in both RCTs and non-RCTs. In all study groups, the incidence rate of minor complications is significantly higher than that of major complications \((P\text{-value} < .0001)\).

#### The Use of Ultrasound Guidance

Several studies have investigated the role of ultrasound guidance in reducing transfemoral access-site complications. One study by Dudeck et al.\(^5\) showed a significant decrease in time to arterial puncture and number of attempts for successful puncturing only in patients with weak femoral pulse or leg circumference \(>60 \text{ cm}\). Another recently published randomized controlled trial (SURF) showed that there was no difference in the complication rates between standard and ultrasound guidance \((P = .76)\). However, ultrasound guidance reduced mean access time \((93 \text{ vs } 111 \text{ s}; P = .009)\), attempts \((1.47 \text{ vs } 1.9; P < .0001)\), and venipuncture \((4.1\% \text{ vs } 9.2\%; P < 0.0001)\) and improved first-pass success \((73\% \text{ vs } 59.7\%; P = .0001)\). On the other hand, a single-center retrospective cohort study on 387 patients undergoing transcatheter aortic valve replacement (TAVR) found that the routine use of ultrasound in transfemoral TAVR was associated with significant reductions in access-related vascular and bleeding complications \((\text{odds ratio [OR]} = 0.42 \text{ [95\% CI, 0.25-0.70]; } P < .01)\).\(^5\) Another recent meta-analysis of 5 RCTs found that ultrasound guidance significantly improves time to access \((\text{weighted mean difference: } 24.90 \text{ min, 95\% CI 12.41-37.38})\), first-pass success rate \((\text{OR } 2.97; 95\% \text{ CI } 1.49-5.92))\), and total complication rate \((\text{OR } 0.42, 95\% \text{ CI } 0.23-0.77)\) but did not have any significant influence on the incidence rate of individual complications like groin hematoma, retroperitoneal hematoma, or pseudoaneurysm.\(^5\)

### Access-Site Complications in Cardiovascular and Other Interventional Procedures

Before we end our discussion, it is important to review the literature in this matter relating to cardiovascular and other interventional procedures. Several studies reported incidence rates of access-site complications in transfemoral catheterization ranging from 1% to 10%.\(^6\) Compared to the transradial approach, transfemoral access had a higher overall rate of access-site complications in the ACUITY trial (3.7 vs 1.4%; \(P < .0001\)). This trial also showed that the rates of bleeding complications are also higher in the transfemoral approach (4.5 vs 1.9%; \(P < .0001\)). Moreover, the rate of pseudoaneurysm was also significantly higher in the transfemoral approach (0.6 vs 0.2%; \(P = .006\)).\(^6\) Additionally, the MATRIX trial showed a significant decrease in bleeding complication in the transradial approach (1.6 vs 2.3%; \(P = .013\)).\(^6\) On the other hand, the RIVAL trial did not show significant differences in terms of primary or secondary endpoints between radial and femoral approaches.\(^6\) A meta-analysis of 12 RCTs by Agostoni et al.\(^6\) concluded that the transradial approach was significantly superior to femoral access in terms of the risk of entry site complications in cardiovascular diagnostic and interventional procedures (0.3% vs 2.8%; OR 0.20, 95% CI 0.09-0.42; \(P < .0001\)).

### Limitations

One of the limitations faced during our study is the differences in the definitions of access-site complications among different trials, along with the difference in the threshold for reporting these complications. This difference may lead to an underestimation of the incidence rates in some studies due to underreporting when thresholds are higher. Another limitation is that some studies were only interested in reporting specific

<table>
<thead>
<tr>
<th>Complication type</th>
<th>Minor n/N (%)</th>
<th>Major n/N (%)</th>
<th>(P) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCTs</td>
<td>116/2847 (4.07%)</td>
<td>25/2719 (0.92%)</td>
<td>(&lt;.0001)</td>
</tr>
<tr>
<td>Non-RCTs</td>
<td>979/34414 (2.84%)</td>
<td>71/33729 (0.21%)</td>
<td>(&lt;.0001)</td>
</tr>
<tr>
<td>Non-RCTs with VCDs</td>
<td>67/3272 (2.05%)</td>
<td>27/3272 (0.83%)</td>
<td>(&lt;.0001)</td>
</tr>
</tbody>
</table>
complications without the others, which led us to exclude their population when calculating the average incidence rates, thus leading to a smaller total population. Moreover, a major limitation is the lack of studies that specifically target access-site complications in neurointerventional procedures. Studies found in the literature mention access-site complications in terms of incidence only, without providing specific patient information like age, anticoagulation status, present comorbidities, or previous interventions at the same site. Those studies also fail to provide details about the technique used, sheath size, and level of heparinization. An alternative route, mainly the transradial, which is gaining a lot of field. This review will allow further studies to compare access-site complications between the transfemoral approach and other alternative routes, mainly the transradial, which is gaining a lot of interest nowadays.

Disclosures
Dr Jabbour is a consultant for Medtronic. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Jabbour is a consultant for MicroVention. Dr Tjoumakaris is a consultant for Stryker.

REFERENCES